EB-1020 (Centanafadine) 328.8 mg

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Co., Ltd.

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

RecruitingNCT06931080

Otsuka Pharmaceutical Co., Ltd.Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2025-04-30End: 2027-12-31Target: 630Updated: 2025-08-03

Phase 3

A Long-term Trial of EB-1020 in Adult Patients With ADHD

RecruitingNCT06926829

Otsuka Pharmaceutical Co., Ltd.Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2025-06-25End: 2027-12-31Target: 180Updated: 2025-08-03